Manufacturing

Process development and antibody manufacturing are core competences of BioInvent. We have a cGMP-certified manufacturing facility, which meets FDA and EU standards for production of antibodies for uses ranging from research, early clinical development through to commercialisation. We use this facility to produce materials for our own clinical trials. As such we can maintain full control of this important part of the drug development process, which is beneficial from a quality, a timeline and also a cost perspective.

BioInvent has a multi-product facility consisting of three culture suites with purification capacity.

Our in-house cell line development team works closely with the process development and cGMP manufacturing teams. We have extensive experience in developing stable antibody-secreting CHO and NS0 cell lines. Using the Lonza GS gene expression system, we can generate stable cell lines within six months, with expression levels meeting the best industry standard.